Development of novel "patient-tailored DDS"by plasma technique

利用等离子体技术开发新型“患者定制DDS”

基本信息

批准号：
14370730
负责人：
KUZUYA Masayuki
金额：
$ 8.26万
依托单位：
Gifu Pharmaceutical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14370730/
关键词：
plasma treatment patient-tailored DDS time-controlled DDS intragastric floating DDS drv orocess crosslinking reaction controlled release oral drug delivery ラグタイム熱効果ガラス転移点

项目摘要

Although oral delivery is convenient to administration and acceptable for patients, the therapeutic effects often depend on the each patient's gastrointenstinal (GI) environment. Therefore, the "Patient-Tailored Drug Delivery System (DDS)" should be developed and administered based on the diagnosis of each patient's GI environment. We have studied plasma-assisted preparation of time-controlled DDS and intragastric floating DDS (FDDS) leading to the "Patient-Tailored DDS" targeting the GI tract. Double-compressed tablets composed of drug tablet as a core material and polymer powder, which was used as pharmaceutical aids, as a wall material was prepared to fabricate time-controlled DDS and inttragastric FDDS.Since plasma-crosslinkable acrylic monomers are one of the component polymers in Eudragits L100-55, argon plasma-irradiation would lead to the suppression of Eudragit L100-55 solubility even in a dissoluble pH-value solution due to the occurrence of the surface cross-link reactions. … More When Eudragit L100-55 is used as a wall material of the double-compressed tablet, the initial drug release could be completely sustained for a certain period of time. The lag-time could be controlled by plasma operational conditions.We have obtained the intragastric FDDS by plasma-irradiation when the double-compressed tablet was prepared using the outer layer to trap evolved carbon dioxide. The double-compressed tablet was prepared using methyl vinyl ether-maleic anhydride copolymer (VEMA), and a mixture of VEMA and hydroxypropyl methylcellulose phthalate as an outer layer. It was found that the tablet plasma-irradiated remains buoyant in the simulated gastric fluids for a prolonged period of time, and the drug release is considerably suppressed. The drug release can be controlled at a desired rate from the tablets by selecting the plasma operational tunings.The present results have clearly shown that one can prepare a variety of desired DDS devices, if one selects the tailored-polymers for wall materials of double-compressed tablets as well as plasma operational conditions. Less

虽然口服给药方便且为患者所接受，但治疗效果往往取决于每个患者的胃肠（GI）环境，因此，应根据诊断开发和施用“患者定制给药系统（DDS）”。我们研究了血浆辅助制备时间控制 DDS 和胃内漂浮 DDS (FDDS)，从而实现针对胃肠道的“患者定制 DDS”。以药物片剂为芯材，以聚合物粉末为药用助剂，为壁材，制备双压片，制备时间控制DDS和胃内FDDS。 Eudragits L100-55 中的聚合物，即使在可溶性 pH 值下，氩等离子体照射也会导致 Eudragits L100-55 溶解度受到抑制由于表面交联反应的发生，Eudragit L100-55用作双压片的壁材料时，初始药物释放可以完全持续一段时间的滞后。 -时间可以通过等离子体操作条件来控制。当使用外层捕获逸出的二氧化碳来制备双重压缩片剂时，我们通过等离子体照射获得了胃内FDDS。双重压缩片剂是使用甲基乙烯基制备的。醚-马来酸酐共聚物（VEMA），以及VEMA和羟丙基甲基纤维素邻苯二甲酸酯的混合物作为外层发现，经辐照的血浆片剂在模拟胃液中保持长时间的浮力，并且药物释放。通过选择等离子体操作调节，可以将药物从片剂中释放控制在所需的速率。目前的结果清楚地表明，可以制备多种药物。如果选择定制聚合物作为双压缩片剂的壁材料以及等离子体操作条件，则所需的 DDS 设备的数量更少。